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Abstract
Background: Behcet’s disease (BD) is characterized by systemic recurrent inflammation with increased production
of tumor necrosis factor (TNF)–α and interleukin (IL)-6 by peripheral blood mononuclear cells (PBMCs). To gain
insight into the underlying mechanisms of this disease, the expression levels of distinct microRNAs in PBMCs of BD
patients were determined and their association with TNF-α and IL-6 production was evaluated.
Findings: The expression levels of microRNAs, miR-638 and miR-4488, were reduced in patients with stable BD in
comparison with healthy controls. In addition, the expression of miR-3591-3p was increased in patients with active BD
when compared to patients with stable BD. Transfection of miR-638 and miR-4488 inhibitors, together with miR-3591-3p
mimics, increased IL-6 mRNA levels in THP-1 cells in response to LPS stimulation.
Conclusions: We observed differential expression of microRNAs associated with increased production of IL-6 in BD
patients.
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Background
Behçet disease (BD) is a relapsing inflammatory disease
characterized by oral ulcers, genital ulcers, skin lesions
and ocular inflammation [1]. It has been proposed that
the development of BD is associated with barrier dys-
function and abnormal innate immune reactions in
environmentally exposed organs, triggering neutrophilic
inflammation [2]. Expression of proinflammatory cyto-
kines in peripheral blood monocytes is increased com-
pared to healthy controls at basal state and in response
to stimulation with lipopolysaccharide (LPS) [3]. Cur-
rently, TNF-α neutralizing antibodies are used to treat
BD. Based upon the experience of several case reports,
IL-6 neutralizing antibodies seem also to be promising
for BD patients with refractory uveitis and central ner-
vous system involvement [4]. However, the underlying
mechanisms for increase in proinflammatory cytokine
levels remain elusive.
MicroRNAs, regulating gene expression through trans-
lational inhibition of target genes, are involved in auto-
immune diseases. Mice that are deficient in miR-155 are
highly resistant to experimental autoimmune encephal-
itis [5]. A role for microRNAs has been suggested in
several autoimmune diseases, including BD [6].
In this study, we analyzed the expression of selected
microRNAs in PBMCs of BD patients and investigated
their roles in the expression of TNF-α and IL-6.
Methods
Study subjects
Patients with BD who visited the Department of Derma-
tology at the Ajou University Hospital and were
diagnosed according to the International Study Group
and Japanese criteria for BD were enrolled in this study.
The patients with active BD exhibited at least one of the
symptoms of BD, despite the medication, whereas the
symptoms were well-controlled in the patients with
stable BD. Clinical features and medications at the time
of inclusion are summarized in Table 1. Healthy
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volunteers were included as a control group. All subjects
provided informed consent for the study, which was
approved by the local Institutional Review Board
(AJIRB-GEN-GEN-10-119).
Cell stimulation
PBMCs were separated using Ficoll-Paque Plus (StemCell
Technologies, Vancouver, Canada) and CD11b + cells were
isolated using magnetic beads (Miltenyi Biotec, Bergisch
Gladbach, Germany). The purity of CD11b + cells was
analyzed by flow cytometry. The cells (3 × 106/mL) were
stimulated with 10 ng/mL LPS (Sigma-Aldrich, St Louis,
MO) for 3 h in RPMI1640 medium (Invitrogen, Gaithers-
burg, MD) containing 10 % fetal bovine serum (Invitro-
gen), penicillin (100 U/mL, Invitrogen) and streptomycin
(100 μg/mL, Invitrogen).
Real-time reverse transcription-polymerase chain reaction
(qRT-PCR)
Total RNA was extracted with TRIzol (Invitrogen). qRT-
PCR was performed using specific primers for IL-6 and
TNF-α. For quantification of microRNA, standard Taq-
Man small RNA assay kit and the TaqMan Universal
PCR Master Mix (Applied Biosystems) were used. RNU-
66 was used to normalize the PCR data. PCR was run on
an ABI PRISM 7000 Sequence Detection System.
Transfection of microRNA mimics and inhibitors
THP-1 cells (2.5 × 104) were transfected with a 40 nM
mixture of equal amount of miR-638 inhibitor, miR-3591-
3p mimic and mir-4488 inhibitor (Ambion, Carlsbad, CA,
USA) or a mixture of control mimics and inhibitors using
lipofectamine 2000 (Invitrogen). FAM-conjugated control
mimics (1/10 of the total amount of mimics and inhibi-
tors) were cotransfected to determine the transfection
efficiency. Cells were stimulated with LPS (10 ng/ml) for
3 h at 21 h post transfection and then subjected to RNA
isolation.
Statistics
Kruskal-Wallis test with Dunn’s procedure for multiple
comparison or Student’s t-test were used to determine P
values. Differences with a P-value < 0.05 were considered
significant.
Results and discussion
Preliminary results from a microRNA microarray
analysis using RNA samples isolated from PBMCs of BD
patients suggested that six microRNAs were differen-
tially expressed between BD patients according to the
levels of IL-6 and TNF-α expression (data not shown).
We therefore examined the expression levels of four
selected microRNAs (miR-638, miR-4488, miR-3591-3p
and miR-1915) using real-time RT-PCR (Fig. 1). Com-
pared to healthy controls, miR-638 expression was 5-fold
reduced in PBMCs from stable BD patients regardless of
LPS stimulation (p < 0.001). Expression of miR-4488 was
approximately 25 % that of healthy controls in PBMCs
from stable BD patients, in the absence of LPS stimulation
(p < 0.01). LPS stimulation increased miR-4488 levels in
PBMCs from stable BD patients to the levels observed in
PBMCs from healthy controls. The levels of miR-3591-3p
in PBMCs from stable BD patients were approximately
one third of those of healthy controls both in the presence
and absence of LPS stimulation, even though there was no
statistical significance. In contrast, miR-3591-3p expres-
sion in PBMCs of active BD patients was significantly in-
creased compared to stable BD patients (p < 0.01).
Expression levels of miR-1915 were not significantly dif-
ferent between study groups. The expression of these
microRNAs was not associated with the clinical symp-
toms, HLA-B51 genotype or medication.
We then determined the levels of TNF-α and IL-6
mRNA in CD11b+ and CD11− cell populations from
PBMCs of BD patients (Fig. 2). TNF-α expression was
significantly increased in both cell populations from
patients with active BD when compared to patients with
stable BD, regardless of LPS stimulation (p < 0.05). In
the absence of LPS stimulation, IL-6 expression was sig-
nificantly increased in both cell populations from pa-
tients with stable BD compared to healthy controls.
However, LPS-stimulated IL-6 expression was signifi-
cantly upregulated in CD11b + cells from patients with
active BD compared to those with stable BD (p < 0.05).







Age (mean age ± SD) 29.3 ± 4.5 43.2 ± 11.0 44.8 ± 4.3
Sex (male : female) 4:4 7:3 5:6
Clinical features of BD patients Case No (%)
Oral ulcer 1 (9.1)
Erythema nodosum 6 (54.5)
Ocular symptoms 4 (36.4)
Arthralgia 1 (9.1)
Gastrointestinal involvement 1 (9.1)
Neurological involvement 1 (9.1)
HLA-B51 5 (50) 6 (54.5)
Medication
Immunosuppressive agentsa 2 (20) 7 (63.7)
Colchicine 10 (100) 10 (90.9)
other antiinflammatory agentsb 9 (90) 10 (90.9)
Minocycline 1 (10) 5 (45.5)
a prednisolone or azathioprine
b salazopyrin or pentoxyfylline or aspirin




Fig. 1 Differential expression of microRNAs in PBMCs from patients with Behcet’s disease (BD). PBMCs from healthy controls (HC, n = 5), stable BD
patients (St, n = 5 or 6) and active BD patients (Ac, n = 6 or 7) were stimulated with LPS (10 ng/mL) for 3 h or left untreated. Expression levels of
miR-638 (a), miR-4488 (b), miR-3591-3p (c) and miR-1915 (d) were analyzed by qRT-PCR. Fold over HC(−): Relative microRNA levels versus the average
microRNA level in HC PBMCs without LPS stimulation. Each symbol represents a single subject. Bars represent the mean of each group. **P < 0.01,
***P < 0.001. P values were calculated using the Kruskal-Wallis test with Dunn’s procedure for multiple comparisons
(A) (B)
Fig. 2 Differential mRNA expression of proinflammatory cytokines in CD11b + and CD11b- cells from BD patients. CD11b + and CD11b- cells
isolated from 3 healthy controls (HC), 3 stable BD patients (St) and 3 active BD patients (Ac) were cultured with or without LPS for 3 h. mRNA
levels of the indicated genes were analyzed by qRT-PCR. Fold over HC(−): Relative mRNA level versus the average mRNA level in CD11b- cells of
HC without LPS stimulation. Each symbol represents a single subject. Bars represent the mean of each group. *P < 0.05. P values were calculated
using the Kruskal-Wallis test with Dunn’s procedure for multiple comparisons
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To understand the relevance of these microRNAs in
inflammatory cytokine production, we transfected THP-
1 cells with a mixture of inhibitors for miR-638 and
miR-4488 together with mimics of miR-3591-3p, and
then analyzed mRNA levels of TNF-α and IL-6 (Fig. 3).
Compared to cells transfected with a mixture of control
microRNA mimics and inhibitors, LPS-stimulated IL-6
mRNA levels were approximately 2.5 fold increased in
cells transfected with inhibitors of miR-638 and miR-
4488 together with mimics of miR-3591-3p (p < 0.05);
however, TNF-α mRNA levels were not different.
Additionally, neither a combination of inhibitors of miR-
638 and miR-4488, nor a combination of mimics of
miR-3591-3p, with either a miR-638 inhibitor or a miR-
4488 inhibitor, affected IL-6 mRNA levels in transfected
cells (data not shown). Taken together, differential ex-
pression of miR-638, miR-4488 and miR-3591-3p was
observed in PBMCs of BD patients and its association
with IL-6 expression was demonstrated.
Recently, differential expression of microRNAs in BD
has been reported. miR-155 expression has been found
to be decreased in BD with uveitis compared to that in
the healthy controls [7]. Additionally, miR-23b was
decreased in CD4+ T cells of BD patients with active
uveitis. This decrease was suggested to be involved in
Th17 response through the activation of the Notch path-
way [8]. Differential expression of miR-720 and miR-
139-3p in PBMCs from BD compared to healthy
controls has been published [9]. Our study is the first to
discover altered expression of miR-638, miR-4488 and
miR-3591-3p associated with BD. Differential expression
of these microRNAs has been associated with several
disorders, such as breast carcinoma and systemic lupus
erythematosus for miR-638 [10, 11], and Barrett’s
esophagus for miR-4488 [12]. However, little information
is currently available on the role of these microRNAs.
Identified targets for miR-638 include BRCA1, sex deter-
mining region Y (SRY)-box (SOX) 2, cyclin-dependent
kinase 2 and tumor protein p53 inducible nuclear
protein 2, human (TP53INP2), which are involved in
proliferation, apoptosis and DNA repair in tumor cells
[10, 13–15]. Given that infections with viruses such as
hepatitis B virus, hepatitis C virus and Chikungunya
virus increase miR-638 expression [16] and that herpes
virus is believed to be involved in BD pathogenesis, it is
possible that underlying viral infection and/or associated
inflammation affect microRNA expression in patients
with BD. Although further studies are required to under-
stand the implications of differential expression of these
microRNAs in BD pathogenesis, we demonstrated that
inhibitors of miR-638 and miR-4488 together with miR-
3591-3p mimics could upregulate IL-6 mRNA levels.
In conclusion, our results demonstrated differential
expression of microRNAs in PBMCs from patients with
BD and suggested that these molecules played a regula-
tory role in the production of IL-6. Further studies re-
garding the mechanisms underlying differential
expression of these microRNAs in PBMCs from patients
with BD is warranted to elucidate the pathogenesis and
identify new therapeutic targets for BD.
Additional file
Additional file 1: Table S1. Differentially expressed microRNAs
between BD responders and nonresponders to colchicine treatment.
(DOCX 11 kb)
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Fig. 3 Upregulation of IL-6 transcript levels by transfection of microRNA inhibitors and mimics. THP-1 cells (2.5 × 104) were transfected with inhibitors
for miR-638 and miR-4488 together with mimics for miR-3591-3p (miRNA) or with a mixture of control inhibitors and mimics (con). PAM-control micro-
RNA (1/10) was cotransfected to determine the transfection efficiency. After 21 h, cells were stimulated with LPS (10 ng/mL) for 3 h and mRNA levels
of TNF-α (a) and IL-6 (b) were assessed by qRT-PCR. Independent experiments were repeated more than three times in duplicate or quadruplicate.
Relative TNF-α expression: mRNA level/average mRNA level of con in the absence of LPS. Relative IL-6 expression: mRNA level/average mRNA level of
con in the presence of LPS. N.D.; not detected, **P < 0.005. Student’s t-test was used for the calculation of P values
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